nach oben

International Journal of Clinical Oncology

Erschienen in:

06.05.2019 | Computed Tomography

Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A)

verfasst von: Shun Sasaki, Eiji Oki, Hiroshi Saeki, Takayuki Shimose, Sanae Sakamoto, Qingjiang Hu, Kensuke Kudo, Yasuo Tsuda, Yuichiro Nakashima, Koji Ando, Yoshito Akagi, Yoshihiro Kakeji, Hideo Baba, Yoshihiko Maehara

Erschienen in: International Journal of Clinical Oncology | Ausgabe 10/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Sarcopenia or degenerative loss of skeletal muscle mass is related to poor prognosis in patients with cancer. This study aimed to clarify the clinical significance of skeletal muscle loss (SML) during chemotherapy for metastatic colorectal cancer (mCRC).

Methods

A total of 249 patients who were secondarily registered in a pooled database of mCRC patients with the first-line systemic chemotherapy and prospectively enrolled in six clinical trials of Kyushu Study Group of Clinical Cancer were included in this study. Skeletal muscle area was calculated from computed tomography images before and 3 and 6 months after treatment. Baseline sarcopenia and SML (cut-off value = 9%) were evaluated.

Results

Baseline sarcopenia was observed in 135 of 219 patients who were evaluated before treatment. They tended to be male; older; and have lower body mass index, lower visceral and subcutaneous fat contents, and a lower waist circumference (P < 0.01); however, baseline sarcopenia was not associated with prognosis. SML at 3 months was associated with an incidence of adverse events (P = 0.01), poor objective response rate (ORR) (P < 0.01), and poor progression-free survival (PFS) (P = 0.03), and it was an independent predictive factor for poor ORR (P < 0.01) and PFS (P = 0.04).

Conclusion

SML at 3 months after systemic chemotherapy for mCRC was associated with poor treatment response. Thus, clarifying the importance of SML prevention guarantees a more effective chemotherapy.

Nur mit Berechtigung zugänglich

Watanabe T, Muro K, Ajioka Y et al (2018) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol 23:1–34. https://doi.org/10.1007/s10147-017-1101-6 CrossRefPubMed

Scheithauer W, Rosen H, Kornek GV et al (1993) Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 306:752–755. https://doi.org/10.1177/2325967117745788 CrossRefPubMedPubMedCentral

Simmonds PC (2000) Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 321:531–535CrossRefPubMed

Cunningham D, Pyrhonen S, James RD et al (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413–1418. https://doi.org/10.1016/S0140-6736(98)02309-5 CrossRefPubMed

Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019. https://doi.org/10.1200/JCO.2007.14.9930 CrossRefPubMed

Adam R, Wicherts DA, de Haas RJ et al (2009) Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 27:1829–1835. https://doi.org/10.1200/JCO.2008.19.9273 CrossRefPubMed

Rosenberg IH (1997) Sarcopenia: origins and clinical relevance. J Nutr 127:990S–S991. https://doi.org/10.1093/jn/127.5.990S CrossRefPubMed

Rosenberg IH (1989) Epidemiologic and methodologic problems in determining nutritional status of older persons. Proceedings of a conference. Albuquerque, New Mexico, October 19–21, 1988. Am J Clin Nutr 50:1121–1235CrossRef

Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al (2010) Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing 39:412–423. https://doi.org/10.1093/ageing/afq034 CrossRefPubMedPubMedCentral

10.

Saeki H, Nakashima Y, Kudou K et al (2018) Neoadjuvant chemoradiotherapy for patients with cT3/nearly T4 esophageal cancer: is sarcopenia correlated with postoperative complications and prognosis? World J Surg 42:2894–2901. https://doi.org/10.1007/s00268-018-4554-5 CrossRefPubMed

11.

Takamori S, Toyokawa G, Okamoto T et al (2018) Clinical impact and risk factors for skeletal muscle loss after complete resection of early non-small cell lung cancer. Ann Surg Oncol 25:1229–1236. https://doi.org/10.1245/s10434-017-6328-y CrossRefPubMed

12.

Nakanishi R, Oki E, Sasaki S et al (2018) Sarcopenia is an independent predictor of complications after colorectal cancer surgery. Surg Today 48:151–157. https://doi.org/10.1007/s00595-017-1564-0 CrossRefPubMed

13.

Kudou K, Saeki H, Nakashima Y et al (2017) Prognostic significance of sarcopenia in patients with esophagogastric junction cancer or upper gastric cancer. Ann Surg Oncol 24:1804–1810. https://doi.org/10.1245/s10434-017-5811-9 CrossRefPubMed

14.

Harimoto N, Yoshizumi T, Shimokawa M et al (2016) Sarcopenia is a poor prognostic factor following hepatic resection in patients aged 70 years and older with hepatocellular carcinoma. Hepatol Res 46:1247–1255. https://doi.org/10.1111/hepr.12674 CrossRefPubMed

15.

Miyamoto Y, Baba Y, Sakamoto Y et al (2015) Negative impact of skeletal muscle loss after systemic chemotherapy in patients with unresectable colorectal cancer. PLoS ONE 10:e0129742. https://doi.org/10.1371/journal.pone.0129742 CrossRefPubMedPubMedCentral

16.

Blauwhoff-Buskermolen S, Versteeg KS, de van der Schueren MA et al (2016) Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer. J Clin Oncol 34:1339–1344. https://doi.org/10.1200/JCO.2015.63.6043 CrossRefPubMed

17.

Oki E, Emi Y, Akagi Y et al (2013) Phase II trial of alternating mFOLFOX6 and FOLFIRI regimens in the first-line treatment for unresectable or metastatic colorectal cancer (KSCC0701). Oncology 84:233–239. https://doi.org/10.1159/000346690 CrossRefPubMed

18.

Miwa K, Oki E, Emi Y et al (2016) Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801). Int J Clin Oncol 21:110–117. https://doi.org/10.1007/s10147-015-0850-3 CrossRefPubMed

19.

Beppu T, Emi Y, Tokunaga S et al (2014) Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 Study). Anticancer Res 34:6655–6662PubMed

20.

Ogata Y, Shimokawa M, Tanaka T et al (2016) A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902). Int J Clin Oncol 21:335–343. https://doi.org/10.1007/s10147-015-0895-3 CrossRefPubMed

21.

Oki E, Emi Y, Miyamoto Y et al (2015) Phase II trial of S-1 and oxaliplatin plus cetuximab for colorectal cancer patients with initially unresectable or not optimally resectable liver metastases (KSCC1002). Ann Surg Oncol 22(Suppl 3):S1067–S1074. https://doi.org/10.1245/s10434-015-4771-1 CrossRefPubMed

22.

Ando K, Emi Y, Suenaga T et al (2017) A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101). Int J Clin Oncol 22:913–920. https://doi.org/10.1007/s10147-017-1140-z CrossRefPubMed

23.

Shen W, Punyanitya M, Wang Z et al (1985) (2004) Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol 97:2333–2338. https://doi.org/10.1152/japplphysiol.00744.2004 CrossRef

24.

Mourtzakis M, Prado CM, Lieffers JR et al (2008) A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 33:997–1006. https://doi.org/10.1139/H08-075 CrossRefPubMed

25.

Mitsiopoulos N, Baumgartner RN, Heymsfield SB et al (1998) Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol (1985) 85:115–122. https://doi.org/10.1152/jappl.1998.85.1.115 CrossRef

26.

Miller KD, Jones E, Yanovski JA et al (1998) Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 351:871–875. https://doi.org/10.1016/S0140-6736(97)11518-5 CrossRefPubMed

27.

Prado CM, Lieffers JR, McCargar LJ et al (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9:629–635. https://doi.org/10.1016/S1470-2045(08)70153-0 CrossRefPubMed

28.

Oka R, Kobayashi J, Yagi K et al (2008) Reassessment of the cutoff values of waist circumference and visceral fat area for identifying Japanese subjects at risk for the metabolic syndrome. Diabetes Res Clin Pract 79:474–481. https://doi.org/10.1016/j.diabres.2007.10.016 CrossRefPubMed

29.

Fearon K, Strasser F, Anker SD et al (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12:489–495. https://doi.org/10.1016/S1470-2045(10)70218-7 CrossRefPubMed

30.

Skipworth RJ, Stewart GD, Dejong CH et al (2007) Pathophysiology of cancer cachexia: much more than host–tumour interaction? Clin Nutr 26:667–676. https://doi.org/10.1016/j.clnu.2007.03.011 CrossRefPubMed

31.

Zhou T, Wang B, Liu H et al (2018) Development and validation of a clinically applicable score to classify cachexia stages in advanced cancer patients. J Cachexia Sarcopenia Muscle 9:306–314. https://doi.org/10.1002/jcsm.12275 CrossRefPubMedPubMedCentral

32.

Barret M, Antoun S, Dalban C et al (2014) Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr Cancer 66:583–589. https://doi.org/10.1080/01635581.2014.894103 CrossRefPubMed

33.

Jung HW, Kim JW, Kim JY et al (2015) Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy. Support Care Cancer 23:687–694. https://doi.org/10.1007/s00520-014-2418-6 CrossRefPubMed

34.

Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867. https://doi.org/10.1038/nature01322 CrossRefPubMedPubMedCentral

35.

Barton BE (2001) IL-6-like cytokines and cancer cachexia: consequences of chronic inflammation. Immunol Res 23:41–58. https://doi.org/10.1385/IR:23:1:41 CrossRefPubMed

36.

Argiles JM, Lopez-Soriano FJ (1999) The role of cytokines in cancer cachexia. Med Res Rev 19:223–248CrossRefPubMed

37.

Naito T, Okayama T, Aoyama T et al (2017) Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non-small-cell lung cancer. BMC Cancer 17:571. https://doi.org/10.1186/s12885-017-3562-4 CrossRefPubMedPubMedCentral

38.

Koelwyn GJ, Quail DF, Zhang X et al (2017) Exercise-dependent regulation of the tumour microenvironment. Nat Rev Cancer 17:620–632. https://doi.org/10.1038/nrc.2017.78 CrossRefPubMed

39.

Friedenreich CM, Neilson HK, Farris MS (2016) Physical activity and cancer outcomes: a precision medicine approach. Clin Cancer Res 22:4766–4775. https://doi.org/10.1158/1078-0432.CCR-16-0067 CrossRefPubMed

40.

Gannon NP, Vaughan RA, Garcia-Smith R et al (2015) Effects of the exercise-inducible myokine irisin on malignant and non-malignant breast epithelial cell behavior in vitro. Int J Cancer 136:E197–E202. https://doi.org/10.1002/ijc.29142 CrossRefPubMed

41.

Shao L, Li H, Chen J et al (2017) Irisin suppresses the migration, proliferation, and invasion of lung cancer cells via inhibition of epithelial-to-mesenchymal transition. Biochem Biophys Res Commun 485:598–605. https://doi.org/10.1016/j.bbrc.2016.12.084 CrossRefPubMed

42.

Shi G, Tang N, Qiu J et al (2017) Irisin stimulates cell proliferation and invasion by targeting the PI3K/AKT pathway in human hepatocellular carcinoma. Biochem Biophys Res Commun 493:585–591. https://doi.org/10.1016/j.bbrc.2017.08.148 CrossRefPubMed

43.

Aoi W, Naito Y, Takagi T et al (2013) A novel myokine, secreted protein acidic and rich in cysteine (SPARC), suppresses colon tumorigenesis via regular exercise. Gut 62:882–889. https://doi.org/10.1136/gutjnl-2011-300776 CrossRefPubMed

44.

Fukushima H, Kataoka M, Nakanishi Y et al (2018) Posttherapeutic skeletal muscle mass recovery predicts favorable prognosis in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. Urol Oncol 36:156.e9–156.e16. https://doi.org/10.1016/j.urolonc.2017.09.016 CrossRef

45.

Shachar SS, Williams GR, Muss HB et al (2016) Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer 57:58–67. https://doi.org/10.1016/j.ejca.2015.12.030 CrossRefPubMed

Titel: Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A)
verfasst von: Shun Sasaki
Eiji Oki
Hiroshi Saeki
Takayuki Shimose
Sanae Sakamoto
Qingjiang Hu
Kensuke Kudo
Yasuo Tsuda
Yuichiro Nakashima
Koji Ando
Yoshito Akagi
Yoshihiro Kakeji
Hideo Baba
Yoshihiko Maehara
Publikationsdatum: 06.05.2019
Verlag: Springer Singapore
Schlagwörter: Computed Tomography
Sarcopenia
Computed Tomography
Underweight
Underweight
Erschienen in: International Journal of Clinical Oncology / Ausgabe 10/2019
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-019-01460-8

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A)